QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced
the release of the QIAstat-Dx Analyzer 2.0, including the Software
1.6 upgrade, a significant enhancement to the widely-used
QIAstat-Dx Analyzer 1.0 for reliable, fast and cost-effective
diagnosis of complex syndromes.
The upgraded diagnostic system, powered by the
new QIAstat-Dx Operational Module PRO with a 64‑bit processor and
4GB of RAM, introduces the Remote Results Application, still unique
in the syndromic testing space. The new feature, accessible through
the QIAsphere cloud and exclusively available with QIAstat‑Dx
Analyzer 2.0, allows users to view, comment and confirm diagnostic
test results directly from their desktop and mobile devices in any
location, facilitating seamless collaboration across the healthcare
system.
This enables greater flexibility and
collaboration between central and regional labs, especially in
decentralized testing, reducing diagnostic processing time and
ensuring patients receive accurate results more quickly.
Alternatively, the QIAstat-Dx Analyzer 2.0 enables in-house
visibility of test results over a shared network.
“With the QIAstat-Dx Analyzer 2.0 and the
Software 1.6 upgrade, QIAGEN is committed to transforming the
molecular diagnostics experience by streamlining the connection
between labs and healthcare professionals,” said Fernando Beils,
Senior Vice President, Head of the Molecular Diagnostics Business
Area at QIAGEN. “The integration of the Remote Results Application
enables swift and efficient access to crucial test results,
ensuring timely and accurate diagnoses for enhanced patient
care.”
The QIAsphere Insights epidemiology dashboards
have also been enhanced, allowing users to view local and global
pathogen epidemiology data from all connected QIAstat-Dx
instruments. All data is de‑identified before processing and
adheres to the highest standards of data protection.
Additional upgrades in the QIAstat-Dx Analyzer
2.0 include enhanced instrument responsiveness, automatic software
updates and notifications, support for 12 languages, and improved
remote system management and security features.
The QIAstat-Dx system, designed for laboratory
use, employs cost-efficient, single-use cartridges with built‑in
sample processing and on-board reagents. Utilizing multiplex
real-time PCR, it detects and differentiates between multiple
pathogens, with results in about an hour. QIAstat-Dx also provides
easy‑to‑view cycle threshold (Ct) values and amplification curves,
offering additional insights not available with end-point PCR or
other techniques.
Tests available for the QIAstat-Dx instrument
include a Meningitis/Encephalitis Panel, which analyzes 15
pathogens simultaneously, a Gastrointestinal Panel 2 which
identifies around 20 clinically relevant bacterial, viral, and
parasitic pathogens and a Respiratory SARS-CoV-2 Panel which
detects over 20 viral and bacterial pathogens.[1]
QIAstat-Dx solutions and syndromic tests
supporting disease diagnosis are available in more than 100
countries worldwide. Over 4,000 instruments had been placed
worldwide by the end of 2023. QIAstat‑Dx is available in two
formats: the QIAstat-Dx Analyzer version, which integrates up to
four Analytical Modules, and the QIAstat-Dx Rise higher-capacity
version, providing comprehensive testing for up to 160 tests per
day using eight Analytical Modules.[1]
For more information about the QIAstat-Dx Analyzer 2.0, please
visit:
https://www.qiagen.com/applications/syndromic-testing/products
About QIAGEN
QIAGEN N.V., a Netherlands-based holding
company, is the leading global provider of Sample to Insight
solutions that enable customers to gain valuable molecular insights
from samples containing the building blocks of life. Our sample
technologies isolate and process DNA, RNA and proteins from blood,
tissue and other materials. Assay technologies make these
biomolecules visible and ready for analysis. Bioinformatics
software and knowledge bases interpret data to report relevant,
actionable insights. Automation solutions tie these together in
seamless and cost-effective workflows. QIAGEN provides solutions to
more than 500,000 customers around the world in Molecular
Diagnostics (human healthcare) and Life Sciences (academia, pharma
R&D and industrial applications, primarily forensics). As of
December 31, 2023, QIAGEN employed approximately 6,000 people in
over 35 locations worldwide. Further information can be found at
http://www.qiagen.com.
Forward-Looking Statement
Certain statements contained in this press
release may be considered forward-looking statements within the
meaning of Section 27A of the U.S. Securities Act of 1933, as
amended, and Section 21E of the U.S. Securities Exchange Act of
1934, as amended. To the extent that any of the statements
contained herein relating to QIAGEN’s products, including those
products used in the response to the COVID-19 pandemic, timing for
launch and development, marketing and/or regulatory approvals,
financial and operational outlook, growth and expansion,
collaborations, markets, strategy or operating results, including
without limitation its expected adjusted net sales and adjusted
diluted earnings results, are forward-looking, such statements are
based on current expectations and assumptions that involve a number
of uncertainties and risks. Such uncertainties and risks include,
but are not limited to, risks associated with management of growth
and international operations (including the effects of currency
fluctuations, regulatory processes and dependence on logistics),
variability of operating results and allocations between customer
classes, the commercial development of markets for our products to
customers in academia, pharma, applied testing and molecular
diagnostics; changing relationships with customers, suppliers and
strategic partners; competition; rapid or unexpected changes in
technologies; fluctuations in demand for QIAGEN’s products
(including fluctuations due to general economic conditions, the
level and timing of customers’ funding, budgets and other factors);
our ability to obtain regulatory approval of our products;
difficulties in successfully adapting QIAGEN’s products to
integrated solutions and producing such products; the ability of
QIAGEN to identify and develop new products and to differentiate
and protect our products from competitors’ products; market
acceptance of QIAGEN’s new products and the integration of acquired
technologies and businesses; actions of governments, global or
regional economic developments, weather or transportation delays,
natural disasters, political or public health crises, including the
breadth and duration of the COVID-19 pandemic and its impact on the
demand for our products and other aspects of our business, or other
force majeure events; as well as the possibility that expected
benefits related to recent or pending acquisitions may not
materialize as expected; and the other factors discussed under the
heading “Risk Factors” contained in Item 3 of our most recent
Annual Report on Form 20-F. For further information, please refer
to the discussions in reports that QIAGEN has filed with, or
furnished to, the U.S. Securities and Exchange Commission.
Source: QIAGEN N.V.Category: Corporate
[1] Product availability may differ from country to country
based on regulations and approvals.
John Gilardi
QIAGEN N.V.
+49 2103 29 11711
ir@qiagen.com
Phoebe Loh
QIAGEN N.V.
+49 2103 29 11457
ir@qiagen.com
Thomas Theuringer
QIAGEN N.V.
+49 2103 29 11826
pr@qiagen.com
Daniela Berheide
QIAGEN N.V.
+49 2103 29 11676
pr@qiagen.com
Qiagen NV (NYSE:QGEN)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Qiagen NV (NYSE:QGEN)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024